UNASSIGNED: Type 2 @entity6 is a very prevalent @entity102 . Among dietary factors for its prevention and treatment, interest has grown in satiating fibre (konjac glucomannan) and spirulina. Our previous studies suggest that glucomannan itself and/or in conjunction to spirulina displayed hypolipemic and antioxidant effects when incorporated to squid surimi as functional ingredients. The present study aims to determine whether @entity28128 - enriched or glucomannan plus spirulina-enriched squid-surimi improve plasma @entity413 and insulin levels in Zucker fa/fa @entity35 fed a high saturated fat diet. Twenty four growing @entity35 , divided into three groups, were given modified AIN-93M diets for seven weeks: 30% squid-surimi control diet (C), 30% glucomannan-enriched squid-surimi diet (G) and 30% glucomannan plus spirulina-enriched squid-surimi diet ( @entity1412 ). All @entity35 became @entity1602 and hyperinsulinemics, but G and @entity1412 diets induced significantly lower @entity413 levels (20%; p < 0.05) but did not modify insulinemia with respect to C diet. @entity1412 animals showed higher HOMA-D (p < 0.05) than C ones suggesting @entity101 . Plasma @entity10672 and adiponectin decreased in G and @entity1412 vs. C group (p < 0.05). Adipose adiponectin increased significantly in G and @entity1412 vs. C @entity35 (16-20 times, p < 0.01). @entity10672 in adipose tissue was higher in @entity1412 vs. G group (p < 0.05). In conclusion, both glucomannan-diets were able to reduce @entity4854 and increase adipose tissue adiponectin levels in fa/fa @entity35 , suggesting an anti- @entity1184 and insulin-sensitizing adipokine effect in this tissue. Spirulina inclusion @entity101 . Although results are promising, the utility of consuming glucomannan surimis as part of usual diets demands future studies.

GLUCOMANNAN AND GLUCOMANNAN PLUS SPIRULINA-ENRICHED SQUID-SURIMI ADDED TO HIGH SATURATED DIET AFFECT GLYCEMIA, PLASMA AND ADIPOSE XXXX AND ADIPONECTIN LEVELS IN GROWING FA/FA @entity35 .

@entity10672 :: ('25608(Tax:10116)', 'Gene') :: ['leptin', 'Leptin'] @entity101 :: ('MESH:D006973', 'Disease') :: ['increased insulin availability'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease'] @entity28128 :: ('MESH:C022901', 'Chemical') :: ['glucomannan'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1412 :: ('MESH:D011125', 'Disease') :: ['GS'] @entity1602 :: ('MESH:D006944', 'Disease') :: ['hyperglycemics'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity10672 :: (25608(Tax:10116),Gene) :: ['LEPTIN']
